Societal and Benuvia Ink Pact To Promote Services To Drug Developers

Benuvia Operations, LLC, a U.S.-based drug developer and manufacturer of active pharmaceutical ingredients (APIs) with specialized expertise in controlled substances (cannabinoids and psychedelics), and Societal CDMO, Inc., a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, announced the signing of a co-marketing agreement.

The agreement is designed to allow the companies to promote each other’s complementary contract development and manufacturing services to their respective customer bases and new business prospects. As part of the agreement, the companies will highlight Benuvia’s specific expertise as a manufacturer of drug substance (API) and Societal’s focus on manufacturing drug product. While the agreement is not limited to any specific therapeutic indication or modality, the companies will specifically focus on leveraging their unique expertise in the area of psychedelics to address this expanding drug development market, as per Societal CDMO.

Social CDMO has a wide range of CDMO capabilities Including formulation development, analytical testing, and the production of oral solid dose finished drug products. The company has been producing and handling controlled substances for several decades. The company received approval from the U.S. Drug Enforcement Agency (DEA) in 2023 to expand its Schedule 2 manufacturing registration it had held with the DEA for more than 20 years by including certain Schedule 1 psychedelic compounds in its controlled substance manufacturing registration.

This extension of its controlled substance capacities has set the organization in a solid situation to help clients with the production of great cGMP clinical supplies for the developing number of progressing and arranged clinical preliminaries in the hallucinogenic medication improvement region.